Prevail Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch PRVL and buy or sell other stocks, options, and ETFs commission-free!

About PRVL

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY. 

CEO
Franz F. Hefti, PhD
CEOFranz F. Hefti, PhD
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2017
Founded2017
Employees
Employees

PRVL Key Statistics

Market cap
787.70M
Market cap787.70M
Price-Earnings ratio
-10.03
Price-Earnings ratio-10.03
Dividend yield
Dividend yield
Average volume
1.19M
Average volume1.19M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$23.35
52 Week high$23.35
52 Week low
$9.02
52 Week low$9.02
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.